Perioperatives Hämostasemanagement bei HNO-Eingriffen

Zusammenfassung

Das perioperative Hämostasemanagement gewinnt auch in der Otorhinolaryngologie zunehmend an Bedeutung. Die vorliegende Übersichtsarbeit fasst den aktuellen Stand der Literatur zusammen und erläutert das perioperative Hämostasemanagement. Mit Bezug auf die HNO-Heilkunde werden die allgemeinen Prinzipien der Risikobewertung, Thromboseprophylaxe, und der Überbrückung der Antikoagulation erläutert.

Abstract

Perioperative hemostatic management is increasingly important in Otolaryngology. This review summarizes the key elements of perioperative risk stratification, thromboprophylaxis, and therapies for bridging of antithrombotic treatment. It gives a practical advise based on the current literature with an emphasis for patients undergoing ear-nose-throat surgery.

Schlüsselwörter

Antikoagulation - Thrombozytenaggregationshemmung - Thromboseprophylaxe - Blutungsrisiko - Thromboserisiko

Key words

anticoagulation - platelet inhibition - thromboprophylaxis - bleeding risk - thrombosis risk

• Literatur

• 1 Ortel TL. Perioperative management of patients on chronic antithrombotic therapy. Blood 2012; 120: 4699-4705
• 2 Koscielny J, Ziemer S, Radtke H et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10: 195-204
• 3 Chee YL, Crawford JC, Watson HG, Greaves M. Guidelines on the assessment of bleeding risk prior to surgery or invasive procedures. British Committee for Standards in Haematology. Br J Haematol 2008; 140: 496-504
• 4 Kaplan EB, Sheiner LB, Boeckmann AJ et al. The usefulness of preoperative laboratory screening. JAMA 1985; 253: 3576-3581
• 5 Prim MP, De Diego JI, Jimenez-Yuste V, Sastre N, Rabanal I, Gavilan J. Analysis of the causes of immediate unanticipated bleeding after pediatric adenotonsillectomy. Int J Pediatr Otorhinolaryngol 2003; 67: 341-344
• 6 Myssiorek D, Alvi A. Post-tonsillectomy hemorrhage: an assessment of risk factors. Int J Pediatr Otorhinolaryngol 1996; 37: 35-43
• 7 Scheckenbach K, Bier H, Hoffmann TK et al. Risk of hemorrhage after adenoidectomy and tonsillectomy. Value of the preoperative determination of partial thromboplastin time, prothrombin time and platelet count. HNO 2008; 56: 312-320
• 8 Schwaab M, Hansen S, Gurr A, Dazert S. Significance of blood tests prior to adenoidectomy. Laryngorhinootologie 2008; 87: 100-106
• 9 Eberl W, Wendt I, Schroeder HG. Preoperative coagulation screening prior to adenoidectomy and tonsillectomy. Klin Padiatr 2005; 217: 20-24
• 10 Asaf T, Reuveni H, Yermiahu T et al. The need for routine pre-operative coagulation screening tests (prothrombin time PT/partial thromboplastin time PTT) for healthy children undergoing elective tonsillectomy and/or adenoidectomy. Int J Pediatr Otorhinolaryngol 2001; 61: 217-222
• 11 Pfanner G, Koscielny J, Pernerstorfer T et al. Preoperative evaluation of the bleeding history. Recommendations of the working group on perioperative coagulation of the Austrian Society for Anaesthesia, Resuscitation and Intensive Care. Anaesthesist 2007; 56: 604-611
• 12 Sumnig A, Grotevendt A, Westphal A, Fiene M, Greinacher A, Thiele T. Acquired hemophilia with inhibitors presenting as an emergency: misinterpretation of clotting results during direct oral anticoagulation. Dtsch Arztebl Int 2014; 111: 345-348
• 13 Steiner T. Neue direkte Orale Antikoagulanzien: Was im Notfall zu beachten ist. Dtsch Arztebl International 2012; 109: A-1928-A-1930
• 14 Schmitz EM, Boonen K, van den Heuvel DJ et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography – tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014; 12: 1636-1646
• 15 Knopf A, Freudelsperger L, Stark T, Scherer E. ENT surgery in patients with anticoagulants and platelet aggregation inhibitors. HNO 2014; 62: 350-357
• 16 Moreano EH, Hutchison JL, McCulloch TM, Graham SM, Funk GF, Hoffman HT. Incidence of deep venous thrombosis and pulmonary embolism in otolaryngology-head and neck surgery. Otolaryngol Head Neck Surg 1998; 118: 777-784
• 17 Garritano FG, Lehman EB, Andrews GA. Incidence of venous thromboembolism in otolaryngology-head and neck surgery. JAMA Otolaryngol Head Neck Surg 2013; 139: 21-27
• 18 Thai L, McCarn K, Stott W et al. Venous thromboembolism in patients with head and neck cancer after surgery. Head Neck 2013; 35: 4-9
• 19 Clayburgh DR, Stott W, Cordiero T et al. Prospective study of venous thromboembolism in patients with head and neck cancer after surgery. JAMA Otolaryngol Head Neck Surg 2013; 139: 1143-1150
• 20 Clayburgh D, Stott W, Kochanowski T et al. Prospective study of venous thromboembolism in patients with head and neck cancer after surgery: interim analysis. JAMA Otolaryngol Head Neck Surg 2013; 139: 161-167
• 21 Caprini JA, Arcelus JI, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. Semin Hematol 2001; 38 (2 Suppl 5): 12-19
• 22 Shuman AG, Hu HM, Pannucci CJ, Jackson CR, Bradford CR, Bahl V. Stratifying the risk of venous thromboembolism in otolaryngology. Otolaryngol Head Neck Surg 2012; 146: 719-724
• 23 Sherwood MW, Douketis JD, Patel MR et al. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF). Circulation 2014; 129: 1850-1859
• 24 Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285: 2864-2870
• 25 Kaatz S, Douketis JD, Zhou H, Gage BF, White RH. Risk of stroke after surgery in patients with and without chronic atrial fibrillation. J Thromb Haemost 2010; 8: 884-890
• 26 Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994; 89: 635-641
• 27 Douketis JD, Spyropoulos AC, Spencer FA et al. Perioperative management of antithrombotic therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9^th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e326S-e350S
• 28 Douketis JD. Perioperative management of patients who are receiving warfarin therapy: an evidence-based and practical approach. Blood 2011; 117: 5044-5049
• 29 Sun JC, Davidson MJ, Lamy A, Eikelboom JW. Antithrombotic management of patients with prosthetic heart valves: current evidence and future trends. Lancet 2009; 374: 565-576
• 30 Brener SJ, Kereiakes DJ, Simonton CA et al. Everolimus-eluting stents in patients undergoing percutaneous coronary intervention: final 3-year results of the Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System in the Treatment of Subjects With de Novo Native Coronary Artery Lesions trial. Am Heart J 2013; 166: 1035-1042
• 31 Dangas GD, Serruys PW, Kereiakes DJ et al. Meta-analysis of everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease: final 3-year results of the SPIRIT clinical trials program (Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv 2013; 6: 914-922
• 32 Feres F, Costa RA, Abizaid A et al. Three vs. twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA 2013; 310: 2510-2522
• 33 Spyropoulos AC, Albaladejo P, Godier A et al. Periprocedural antiplatelet therapy: recommendations for standardized reporting in patients on antiplatelet therapy: communication from the SSC of the ISTH. J Thromb Haemost 2013; 11: 1593-1596
• 34 AWMF-Leitlinie Prophylaxe der venösen Thromboembolie (VTE) 2010
• 35 Gould MK, Garcia DA, Wren SM et al. Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9^th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e227S-e277S
• 36 Sarode R, Milling Jr TJ, Refaai MA et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation 2013; 128: 1234-1243
• 37 Beyer-Westendorf J, Forster K, Pannach S et al. Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood 2014; 124: 955-962
• 38 Heidbuchel H, Verhamme P, Alings M et al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J 2013; 34: 2094-2106
• 39 Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood 2012; 119: 2172-2174
• 40 Singh T, Maw TT, Henry BL et al. Extracorporeal therapy for dabigatran removal in the treatment of acute bleeding: a single center experience. Clin J Am Soc Nephrol 2013; 8: 1533-1539
• 41 Selleng K, Thiele T, Sumnig A, Mayerle J, Greinacher A. Dabigatran may redistribute into the vascular compartment after hemodialysis – a case report. Abstract GTH Annual Meeting 2013;
• 42 Schiele F, van Ryn J, Canada K et al. A specific antidote for dabigatran: functional and structural characterization. Blood 2013; 121: 3554-3562
• 43 Lu G, DeGuzman FR, Hollenbach SJ et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med 2013; 19: 446-451
• 44 Thiele T, Althaus K, Greinacher A. Heparin-induced thrombocytopenia. Internist (Berl) 2010; 51: 1127-1132 1134–1135
• 45 Nast A, Ernst H, Rosumeck S, Erdmann R, Jacobs A, Sporbeck B.. Risk of complications due to anticoagulation during dermatosurgical procedures: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2014;
• 46 Birnie DH, Healey JS, Wells GA et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013; 368: 2084-2093
• 47 Devereaux PJ, Mrkobrada M, Sessler DI et al. Aspirin in patients undergoing noncardiac surgery. N Engl J Med 2014; 370: 1494-1503
• 48 Li C, Hirsh J, Xie C, Johnston MA, Eikelboom JW. Reversal of the anti-platelet effects of aspirin and clopidogrel. J Thromb Haemost 2012; 10: 521-528
• 49 Zafar MU, Santos-Gallego C, Vorchheimer DA et al. Platelet function normalization after a prasugrel loading-dose: time-dependent effect of platelet supplementation. J Thromb Haemost 2013; 11: 100-106
• 50 Farid NA, Payne CD, Small DS et al. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin Pharmacol Ther 2007; 81: 735-741
• 51 Jakubowski JA, Payne CD, Li YG et al. A comparison of the antiplatelet effects of prasugrel and high-dose clopidogrel as assessed by VASP-phosphorylation and light transmission aggregometry. Thromb Haemost 2008; 99: 215-222
• 52 Korte W, Cattaneo M, Chassot PG et al. Peri-operative management of antiplatelet therapy in patients with coronary artery disease: joint position paper by members of the working group on Perioperative Haemostasis of the Society on Thrombosis and Haemostasis Research (GTH), the working group on Perioperative Coagulation of the Austrian Society for Anesthesiology, Resuscitation and Intensive Care (OGARI) and the Working Group Thrombosis of the European Society for Cardiology (ESC). Thromb Haemost 2011; 105: 743-749
• 53 Authors/Task Force m Windecker S, Kolh P. et al. 2014; ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014;
• 54 Sylvester DC, Coatesworth AP. Antiplatelet therapy in ENT surgery: a review. J Laryngol Otol 2012; 126: 331-336
• 55 Albaladejo P, Charbonneau H, Samama CM et al. Bleeding complications in patients with coronary stents during non-cardiac surgery. Thromb Res 2014; 134: 268-272
• 56 Savage JR, Parmar A, Robinson PJ. Antiplatelet drugs in elective ENT surgery. J Laryngol Otol 2012; 126: 886-892
• 57 Vaishnava P, Eagle KA. The yin and yang of perioperative medicine. N Engl J Med 2014; 370: 1554-1555
• 58 Vicenzi MN, Meislitzer T, Heitzinger B, Halaj M, Fleisher LA, Metzler H. Coronary artery stenting and non-cardiac surgery – a prospective outcome study. Br J Anaesth 2006; 96: 686-693
• 59 Collet JP, Himbet F, Steg PG. Myocardial infarction after aspirin cessation in stable coronary artery disease patients. Int J Cardiol 2000; 76: 257-258
• 60 Thiele T, Sumnig A, Hron G et al. Platelet transfusion for reversal of dual antiplatelet therapy in patients requiring urgent surgery: a pilot study. J Thromb Haemost 2012; 10: 968-971
• 61 Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J Clin Pharmacol 2010; 50: 126-142
• 62 Butler K, Teng R. Pharmacokinetics, pharmacodynamics, safety and tolerability of multiple ascending doses of ticagrelor in healthy volunteers. Br J Clin Pharmacol 2010; 70: 65-77
• 63 Savonitto S, D’Urbano M, Caracciolo M et al. Urgent surgery in patients with a recently implanted coronary drug-eluting stent: a phase II study of ‘bridging’ antiplatelet therapy with tirofiban during temporary withdrawal of clopidogrel. Br J Anaesth 2010; 104: 285-291
• 64 Angiolillo DJ, Firstenberg MS, Price MJ et al. Bridging antiplatelet therapy with cangrelor in patients undergoing cardiac surgery: a randomized controlled trial. JAMA 2012; 307: 265-274